Antimuscarinics for the treatment of overactive bladder: A review of central nervous system effects

Current Bladder Dysfunction Reports

Volumn 2, Issue 4, 2007, Pages 227-233

  Klausner, Adam P ^a   Steers, William D ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954646255     PISSN: 19317212     EISSN: 19317220     Source Type: Journal    
DOI: 10.1007/s11884-007-0024-x     Document Type: Article

References (45)

1. Abrams P, Cardozo L, Fall M, et al.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21: 167-178.
2. Temml C, Heidler S, Ponholzer A, Madersbacher S: Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol 2005, 48: 622-627.
3. Stewart WF, van Rooyen JB, Cundiff GW, et al.: Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20: 327-336.
4. Coyne KS, Zhou Z, Thompson C, Versi E: The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 2003, 92: 731-735.
5. Darkow T, Fontes CL, Williamson TE: Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 2005, 25: 511-519.
6. Nabi G, Cody JD, Ellis G, et al.: Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006, CD003781.
7. Sanctura (trospium chloride) 20 mg tablets prescribing information. Available at http://www. sanctura. com/pdf/sanctura_pi. pdf. Accessed February 1, 2007.
8. Detrol LA tolterodine tartrate extended release capsules: prescribing information. Available at http://www. detrolla. com/cwpb/appmanager/detrolLA/detrolLADesktop?_nfpb=true&_pageLabel=detrolLA_prescribingInformation. Accessed February 1, 2007.
9. Irwin DE, Milsom I, Hunskaar S, et al.: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006, 50: 1306-1314, discussion 1314-1315.
10. Fick DM, Cooper JW, Wade WE, et al.: Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003, 163: 2716-2724.
11. Scarpero HM, Dmochowski RR: Muscarinic receptors: what we know. Curr Urol Rep 2003, 4: 421-428.
12. Abrams P, Andersson KE, Buccafusco JJ, et al.: Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006, 148: 565-578.
13. Yamada M, Miyakawa T, Duttaroy A, et al.: Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 2001, 410: 207-212.
14. Haab F, Stewart L, Dwyer P: Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004, 45: 420-429, discussion 429.
15. Garely AD, Kaufman JM, Sand PK, et al.: Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther 2006, 28: 1935-1946.
16. Cardozo L, Lisec M, Millard R, et al.: Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004, 172: 1919-1924.
17. Napier C, Gupta P: Darifenacin is selective for the human recombinant M3 receptor subtype [abstract 445]. Presented at the International Continence Society annual meeting. Heidelberg, Germany; August 28-30, 2002.
18. Ikeda K, Kobayashi S, Suzuki M, et al.: M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002, 366: 97-103.
19. Appell RA, Sand P, Dmochowski R, et al.: Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001, 76: 358-363.
20. van Kerrebroeck P, Kreder K, Jonas U, et al.: Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001, 57: 414-421.
21. Kay G, Crook T, Rekeda L, et al.: Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006, 50: 317-326.
22. Sugiyama T, Park YC, Kurita T: Oxybutynin disrupts learning and memory in the rat passive avoidance response. Urol Res 1999, 27: 393-395.
23. Womack KB, Heilman KM: Tolterodine and memory: dry but forgetful. Arch Neurol 2003, 60: 771-773.
24. Tanaka E: In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 1998, 23: 247-255.
25. Gulsun M, Pinar M, Sabanci U: Psychotic disorder induced by oxybutynin: presentation of two cases. Clin Drug Investig 2006, 26: 603-606.
26. Tsao JW, Heilman KM: Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003, 349: 2274-2275.
27. Partridge JG, Apparsundaram S, Gerhardt GA, et al.: Nicotinic acetylcholine receptors interact with dopamine in induction of striatal long-term depression. J Neurosci 2002, 22: 2541-2549.
28. Todorova A, Vonderheid-Guth B, Dimpfel W: Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001, 41: 636-644.
29. Once-a-day Ditropan XL (oxybutynin chloride) extended-release tablets 5, 10, 15 mg. Full U. S. prescribing information. Available at http://www. ditropanxl. com/html/pdxl/prescribing_consumer. jsp; jsessionid=UYLZTKGIQK2EOCQPCCFTC0YKB2IIQNSC? Accessed February 1, 2007.
30. Dmochowski RR, Nitti V, Staskin D, et al.: Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005, 23: 263-270.
31. Enablex (darifenacin) extended release tablets: prescribing information. Available at http://www. enablex. com/info/tools/pi. jsp. Accessed February 1, 2007.
32. VESIcare (solifenacin succinate) tablets. Available at http://www. astellas. us/docs/vesicare. pdf. Accessed February 1, 2007.
33. Diefenback K, Donath F, Maurer A, et al.: Randomized, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in heathy young volunteers. Clin Drug Investig 2003, 23: 395-404. Available at http://druginvestigation. adisonline. com.
34. Ancelin ML, Artero S, Portet F, et al.: Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006, 332: 455-459.
35. Erdincler P, Tuzgen S, Erdincler UD, et al.: Influence of aging on blood-brain barrier permeability and free radical formation following experimental brain cold injury. Acta Neurochir (Wien) 2002, 144: 195-199, discussion 199-200.
36. Abdel-Rahman A, Shetty AK, Abou-Donia MB: Disruption of the blood-brain barrier and neuronal cell death in cingulate cortex, dentate gyrus, thalamus, and hypothalamus in a rat model of Gulf-War syndrome. Neurobiol Dis 2002, 10: 306-326.
37. Sommer BR, O'Hara R, Askari N, et al.: The effect of oxybutynin treatment on cognition in children with diurnal incontinence. J Urol 2005, 173: 2125-2127.
38. Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet 2006, 368: 387-403.
39. Siegler EL, Reidenberg M: Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin Pharmacol Ther 2004, 75: 484-488.
40. Perry EK, Kilford L, Lees AJ, et al.: Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003, 54: 235-238.
41. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, et al.: Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 2006, 24: 516-524.
42. Jankowsky JL, Xu G, Fromholt D, et al.: Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Neuropathol Exp Neurol 2003, 62: 1220-1227.
43. Klausner AP, Fletcher S, Yang SK, et al.: Does oxybutynin alter amyloid beta peptides in a mouse model of Alzheimer's Disease? [abstract]. J Urol 2005, 173: 41.
44. Sharma S, Klausher AP, Fletcher S, et al.: The effect of oxybutynin on plaques, amyloid beta peptides, and behavior in mouse and human cybrid models of Alzheimer's Disease [abstract]. J Urol 2006, 175: 55.
45. Daniel JM, Hulst JL, Lee CD: Role of hippocampal M2 muscarinic receptors in the estrogen-induced enhancement of working memory. Neuroscience 2005, 132: 57-64.